PMID- 35506423
OWN - NLM
STAT- MEDLINE
DCOM- 20220505
LR  - 20220716
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 5
DP  - 2022 May
TI  - Everolimus ameliorates Helicobacter pylori infection-induced inflammation in 
      gastric epithelial cells.
PG  - 11361-11372
LID - 10.1080/21655979.2021.2018533 [doi]
AB  - Helicobacter pylori (H.pylori) infection caused by gastric mucosal inflammation 
      plays a pivotal role in the progression of gastric diseases. The recruitment and 
      attachment of monocytes to the gastric mucosal epithelium are a major event in 
      the early stages of H. pylori-associated gastric diseases. Everolimus is a 
      mechanistic/mammalian target of rapamycin (mTOR) inhibitor used to prevent tumor 
      growth by inhibiting the PI3K signaling pathway. Here, we examined the 
      pharmacological role of Everolimus against H.pylori-induced damage in gastric 
      epithelial cells. Firstly, we found that Everolimus ameliorated H.pylori-induced 
      oxidative stress by reducing reactive oxygen species (ROS) and malondialdehyde 
      (MDA). Secondly, Everolimus significantly reduced the expressions of the 
      pro-inflammatory cytokines interleukin (IL)-6, tumor necrosis factor-alpha (TNF-alpha), 
      and IL-8. Moreover, it decreased the production of the pro-inflammatory 
      chemokines C-X-C motif ligand 1 (CXCL1) and macrophage chemoattractant protein-1 
      (MCP-1). Importantly, Everolimus suppressed the induction of the adhesion 
      molecule intracellular adhesion molecule-1 (ICAM-1) and the attachment of THP-1 
      monocytes to gastric epithelial AGS cells. Our data also shows that Everolimus 
      inhibited the activation of the NF-kappaB signaling pathway. Therefore, we conclude 
      that Everolimus could protect gastric epithelial cells by mitigating 
      H.pylori-induced inflammatory response and the attachment of monocytes to 
      epithelial cells.
FAU - Liu, Jinglei
AU  - Liu J
AD  - Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated 
      to shandong First Medical University, Ji'nan City, Shandong Province, China.
FAU - Zhang, Fangxu
AU  - Zhang F
AD  - Department of Gastrointestinal Surgery, Clinical College of Weifang Medical 
      University, Weifang City, Shandong Province, China.
FAU - Zhang, Zheming
AU  - Zhang Z
AD  - Department of Gastrointestinal Surgery, Clinical College of Weifang Medical 
      University, Weifang City, Shandong Province, China.
FAU - Zheng, Chunning
AU  - Zheng C
AUID- ORCID: 0000-0002-9039-2065
AD  - Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated 
      to shandong First Medical University, Ji'nan City, Shandong Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (Interleukin-8)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Epithelial Cells/metabolism
MH  - Everolimus/metabolism/pharmacology
MH  - *Helicobacter Infections/complications/drug therapy/metabolism
MH  - *Helicobacter pylori/metabolism
MH  - Humans
MH  - Inflammation/drug therapy/metabolism
MH  - Interleukin-8/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
PMC - PMC9276037
OTO - NOTNLM
OT  - Everolimus
OT  - Helicobacter pylori
OT  - NF-kappaB
OT  - gastritis
OT  - inflammation
OT  - monocyte attachment
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/05/05 06:00
MHDA- 2022/05/06 06:00
PMCR- 2022/05/04
CRDT- 2022/05/04 05:23
PHST- 2022/05/04 05:23 [entrez]
PHST- 2022/05/05 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/05/04 00:00 [pmc-release]
AID - 2018533 [pii]
AID - 10.1080/21655979.2021.2018533 [doi]
PST - ppublish
SO  - Bioengineered. 2022 May;13(5):11361-11372. doi: 10.1080/21655979.2021.2018533.